1 Recommendations

1.1 Enzalutamide is recommended, within its marketing authorisation, as an option for treating metastatic hormone‑relapsed prostate cancer:

  • in people who have no or mild symptoms after androgen deprivation therapy has failed, and before chemotherapy is indicated

  • and only when the company provides it with the discount agreed in the patient access scheme.

  • National Institute for Health and Care Excellence (NICE)